Latest News

22.04.2013
Antitope Ltd., Announces Protein Deimmunisation Research Agreement with Research Corporation Technologies, Inc.
Cambridge, UK, 22nd April 2012 - Antitope Ltd, UK ("Antitope") today announced a Research Agreement with Research Corporation Technologies Inc., USA ("RCT") to re-engineer a toxic protein warhead for the next generation of antibody drug conjugates (ADCs) using it's proprietary...

06.02.2013
Antitope Ltd. and Eden Biodesign Ltd. enter into a Research Agreement
Cambridge UK, February 2013 - Antitope Ltd. (UK) today announced a Research Agreement with Eden Biodesign Ltd. (Liverpool, UK) for the development of therapeutic antibodies. As part of the Agreement, Antitope will apply its proprietary technologies towards the generation of a high yielding...

31.01.2013
Antitope and Rottapharm|Madaus Complete Successful Immunogenicity Assessment Research Collaboration
Cambridge UK, January 2013 - Antitope Ltd., UK ("Antitope") today announced the completion of a research collaboration with Rottapharma Biotech Srl, the Antibody Research Unit of the Italian healthcare company Rottapharm|Madaus, whereby Antitope applied is proprietary EpiScreenTM and in...

24.01.2013
Antitope Ltd., Announces Protein Deimmunisation Research Agreement with NeuroPhage Pharmaceuticals, Inc.
Cambridge UK, January 2013 - Antitope Ltd., UK ("Antitope") today announced a Research Agreement with NeuroPhage Pharmaceuticals, Inc., USA ("NeuroPhage") for the generation of a therapeutic protein with reduced immunogenicity. Under the Agreement, Antitope will apply it's...

24.01.2013
Meet Antitope at BIO-Europe Spring (Barcelona 11th-13th March)
Antitope will be participating in the Business Partnering Forum at the BIO-Europe and welcome the opportunity to discuss potential collaborations with companies that are interested in assessing and/or removing immunogenicity from protein therapeutics. Meetings can be arranged through the Conference...